Related Experiment Video

Updated: Jul 23, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Anti-EGF receptor therapy

G Blackledge1, S Averbuch, A Kay

  • 1AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.

Prostate Cancer and Prostatic Diseases
|December 24, 2002
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors like ZD1839 show promise for treating hormone-resistant prostate cancer. Early trials indicate this EGFR-tyrosine kinase inhibitor is well-tolerated and effective against various advanced cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) pathway is crucial for tumor progression, including cell proliferation, apoptosis, angiogenesis, and metastasis.
  • EGFR signaling plays a key role in the survival mechanisms of hormone-resistant prostate cancer.
  • Novel therapeutic strategies are urgently needed for advanced prostate cancer.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ZD1839 (Iressa), a selective EGFR-tyrosine kinase inhibitor, in preclinical models and early-phase clinical trials.
  • To investigate the potential of ZD1839 as a treatment for hormone-resistant prostate cancer.

Main Methods:

  • Preclinical studies involving ZD1839 alone and in combination with cytotoxic agents in various tumor cell lines and human tumor xenografts.
  • Phase I clinical trials in patients with advanced cancers to assess safety, tolerability, and preliminary efficacy.

Main Results:

  • ZD1839 demonstrated reversible tumor growth inhibition and delay in preclinical models.
  • Preliminary Phase I data suggest ZD1839 has an acceptable safety profile.
  • Promising clinical efficacy was observed in patients with various advanced tumor types, including hormone-resistant prostate cancer.

Conclusions:

  • ZD1839 is an orally active, selective EGFR-tyrosine kinase inhibitor with demonstrated preclinical anti-tumor activity.
  • Early clinical data indicate ZD1839 is a potentially valuable therapeutic option for hormone-resistant prostate cancer and other advanced malignancies.
  • Further investigation of ZD1839 in larger clinical trials is warranted.

More Related Videos

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...